The research focus of Allen Andres, PhD, is divided into two main areas: understanding how the metabolic syndrome leads to poor outcome against ischemia/reperfusion injury in the heart, and elucidating the role mitochondrial turnover plays in the etiology of statin-mediated skeletal muscle myopathy. He leads work on the metabolic syndrome issue as a senior member of the lab group of Roberta Gottlieb, MD. The group was the first to demonstrate the importance of mitophagy in ischemic preconditioning. Moreover, it showed that cardioprotective benefit from acute simvastatin administration acts through a similar mechanism that is blocked by the availability of exogenous coenzyme Q10. The mitochondrial work is Andres' first research foray as an independent scientist. A central theme in his investigations is how regulation of mitochondria through autophagy is related to the development or pathology of the aforementioned areas.

• Undergraduate: University of California, Irvine, 2003
• Doctorate: San Diego State University/University of California, San Diego, 2009

View CV as a PDF

• Smidt Heart Institute
• Cardiology
• Medicine

• Scientist Development Grant, American Heart Association, 2015
• Member, American Heart Association, 2011-present

• Huang C, Andres AM, Ratliff EP, Hernandez G, Lee P, Gottlieb RA. Preconditioning involves selective mitophagy mediated by Parkin and p62/SQSTM1. PLoS ONE. 2011;6(6):e20975.
• Andres AM, Hernandez G, Lee P, Huang C, Ratliff EP, Sin J, Thornton CA, Damasco MV, Gottlieb RA. Mitophagy is required for acute cardioprotection by simvastatin. Antioxid Redox Signal. 2014;10;21(14):1960-1973.
• Andres AM, Stotland A, Queliconi BB, Gottlieb RA. A time to reap, a time to sow: mitophagy and biogenesis in cardiac pathophysiology. J Mol Cell Cardiol. 2015;78:62-72.